| Radiopharmaceutical Chemistry and Applications | Lifetime | 28 | US 16 | 99.63 |
| Prostate Cancer Treatment and Research | Lifetime | 39 | US 29 | 99.80 |
| Renal cell carcinoma treatment | Lifetime | 32 | US 25 | 99.75 |
| Occupational and environmental lung diseases | Lifetime | 19 | US 9 | 99.47 |
| Pleural and Pulmonary Diseases | Lifetime | 27 | US 13 | 99.59 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 66 | US 44 | 99.61 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 131 | US 78 | 99.66 |
| Cancer Genomics and Diagnostics | Lifetime | 234 | US 150 | 99.51 |
| Renal and related cancers | Lifetime | 107 | US 70 | 99.31 |
| Testicular diseases and treatments | Lifetime | 48 | US 20 | 99.19 |
| Multiple and Secondary Primary Cancers | Lifetime | 73 | US 31 | 98.96 |
| Cancer Treatment and Pharmacology | Lifetime | 287 | US 159 | 99.13 |
| Urinary and Genital Oncology Studies | Lifetime | 159 | US 93 | 98.86 |
| Cancer Research and Treatments | Lifetime | 323 | US 195 | 98.07 |
| Hormonal and reproductive studies | Lifetime | 289 | US 150 | 98.41 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 367 | US 187 | 98.83 |
| Chemotherapy-related skin toxicity | Lifetime | 60 | US 37 | 97.20 |
| Ferroptosis and cancer prognosis | Lifetime | 334 | US 96 | 96.26 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 63 | US 20 | 96.72 |
| Bone health and treatments | Lifetime | 471 | US 206 | 97.82 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 528 | US 229 | 97.36 |
| Multiple Myeloma Research and Treatments | Lifetime | 509 | US 228 | 97.43 |
| Neuroblastoma Research and Treatments | Lifetime | 677 | US 333 | 96.75 |
| Economic and Financial Impacts of Cancer | Lifetime | 456 | US 295 | 95.39 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 359 | US 180 | 93.47 |
| Neutropenia and Cancer Infections | Lifetime | 641 | US 278 | 94.93 |
| Sexual Differentiation and Disorders | Lifetime | 968 | US 367 | 93.73 |
| Gestational Trophoblastic Disease Studies | Lifetime | 570 | US 214 | 85.69 |
| Prostate Cancer Treatment and Research | 2021-2025 | 417 | US 155 | 96.16 |
| Renal cell carcinoma treatment | 2021-2025 | 400 | US 147 | 93.94 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 555 | US 137 | 90.32 |
| Renal and related cancers | 2021-2025 | 692 | US 257 | 84.54 |
| Chemotherapy-related skin toxicity | 2021-2025 | 866 | US 265 | 28.79 |
